Report
Geir Hiller Holom
EUR 90.34 For Business Accounts Only

PhotoCure (Buy, TP: NOK84.00) - On course for continued growth

Photocure reported its highest-ever quarterly product revenues in Q4, but EBIT was significantly lower than we expected due to the timing of project expenses, negative FX, and inflation. For 2025, the company guided for product revenue growth of 7–11% and a YOY EBITDA improvement. We believe several initiatives support continued growth. We still find the valuation attractive and reiterate our BUY and NOK84 target price.
Underlying
PhotoCure ASA

Photocure is a Norwegian based specialty pharmaceutical company. Co. develops and commercializes solutions in several disease areas such as bladder cancer, colorectal cancer, HPV and precancerous lesions of the cervix, acne and other dermatologic conditions. Co. has one marketed product that Co. commercializes directly in the U.S. and the Nordic region is Hexvix®/Cysview®, for detection of bladder cancer.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Geir Hiller Holom

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch